Document is current
Any future updates will be listed below
-
Authors
Argirò, Alessia
Parikh, Victoria
Jurcut, Ruxandra
Finocchiaro, Gherardo
Kaski, Juan Pablo https://orcid.org/0000-0002-0014-9927
Adler, Eric
Olivotto, Iacopo https://orcid.org/0000-0003-1751-9266
- License Information
-
More Information
Article History
Accepted: 17 July 2025
First Online: 14 August 2025
Competing interests
: A.A. is a consultant for Lexeo Therapeutics. I.O. is a consultant and/or adviser for Amicus Therapeutics, Inc.; Boston Scientific Corporation; Bristol Myers Squibb; Cytokinetics, Inc.; and Tenaya Therapeutics, Inc., and has received grant and/or research support from Amicus Therapeutics, Inc.; Bayer AG; Boston Scientific Corporation; Bristol Myers Squibb; Genzyme Corporation; The Menarini Group; Sanofi; Shire plc; and Takeda Pharmaceuticals International, Inc. E.A. is the Chief Science Officer for Lexeo Therapeutics, a shareholder with Rocket Pharmaceuticals and is a founder of Papillion Therapeutics and a founder, on the scientific board of and a shareholder of Corstasis Therapeutics. The other authors declare no competing interests.
